Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Odyssey Therapeutics, Inc. (ODTX)
Boston, MA, US
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Metric |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
2.98M
est: 2.98M (+0.0%)
|
2.98M
2.98M – 2.98M
+0.0% YoY
|
2.98M
2.98M – 2.98M
+0.0% YoY
|
2.98M
2.98M – 2.98M
+0.0% YoY
|
2.98M
2.98M – 2.98M
+0.0% YoY
|
2.98M
2.98M – 2.98M
+0.0% YoY
|
| EBITDA |
-144.65M
est: -2.98M (-4,760.4%)
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
| EBIT |
-149.56M
est: -2.98M (-4,925.4%)
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
-2.98M
-2.98M – -2.98M
+0.0% YoY
|
| Net Income |
-148.65M
est: -1.17B (+87.3%)
|
-121.64M
-148.80M – -94.47M
+89.6% YoY
|
-109.84M
-133.30M – -86.37M
+9.7% YoY
|
-111.07M
-136.79M – -85.36M
-1.1% YoY
|
-124.48M
-124.48M – -124.48M
-12.1% YoY
|
-126.05M
-126.05M – -126.05M
-1.3% YoY
|
| SGA |
37.52M
est: 37.52M (+0.0%)
|
37.52M
37.52M – 37.52M
+0.0% YoY
|
37.52M
37.52M – 37.52M
+0.0% YoY
|
37.52M
37.52M – 37.52M
+0.0% YoY
|
37.52M
37.52M – 37.52M
+0.0% YoY
|
37.52M
37.52M – 37.52M
+0.0% YoY
|
| EPS |
-5.39
est: -42.60 (+87.3%)
|
-4.54
-5.40 – -3.43
+89.3% YoY
|
-4.19
-4.84 – -3.13
+7.6% YoY
|
-4.30
-4.96 – -3.10
-2.7% YoY
|
-4.52
-4.52 – -4.52
-4.9% YoY
|
-4.57
-4.57 – -4.57
-1.3% YoY
|
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Schwab U.S. Small-Cap ETF SCHA | 0.01% | 1.23M | 0.03% |
| 2 | Vanguard Russell 2000 Growth ETF VTWG | 0.00% | 19.8K | 0.06% |
| 3 | Vanguard Russell 2000 ETF VTWO | 0.00% | 197.3K | 0.06% |
| 4 | Vanguard Russell 2000 Value ETF VTWV | 0.00% | 13.0K | 0.06% |
| 5 | Vanguard Extended Market ETF VXF | 0.00% | 465.1K | 0.05% |
| 6 | Schwab U.S. Broad Market ETF SCHB | 0.00% | 210.5K | 0.03% |
| 7 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 8.2K | 0.17% |
| 8 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 606.01 | 0.17% |
| 9 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.0K | 0.03% |
| 10 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.40M | 0.03% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ODTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
